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Abstract 
Stability is an essential factor of quality, safety and efficacy of a drug product. The objective of stability study 
is to determine the shelf life, the time period of storage at a specified condition within which the drug product 
still meets its established specifications. Stability study is of three types that is physical, chemical and 
microbial stability. Various factors like oxygen, water, temperature, pH, moisture, light and concentration 
affect the stability. Present work aims to represent the stability testing (ST) requirements of International 
Conference on Harmonization (ICH), different regulatory agencies like, World Health Organization (WHO), 
Association of South East Asian Nations (ASEAN) and European Agency for Evaluation of Medicinal and 
Health Products (EMEA) and difference of those agencies with respect to ICH guideline. Most of the stability 
requirements for WHO, ASEAN, and EMEA are similar to the ICH guideline, except for the parameters like 
selection of batches and storage conditions. 
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1. Introduction 
Stability is defined as the capacity of a drug 
substance or drug product to remain within the 
established specifications which maintains its 
identity, strength, quality and purity throughout 
the retest or expiration dating period. The 
objective of stability study is to determine the 
shelf life, namely the time period of storage at a 
specified condition within which the drug 
product still meets its established specifications. 
Stability is an essential factor of quality, safety 
and efficacy of a drug product. A drug product, 
which is not of sufficient stability, can result in 
changes in physical (like hardness, dissolution 
rate, phase separation etc) as well as chemical 
characteristics (formation of high risk 
decomposition substances). The Chemical 
stability of drug is of great importance since it 
becomes less effective as it undergoes 
degradation. Also drug decomposition may yield 
toxic byproducts that are harmful to the patient. 
Microbiological instability of a sterile drug 
product could also be hazardous. Stability 
evaluation of drug substance or drug product is 
the key to drug quality as it determines the 
efficacy of any drug or dosage form. Stability 
assessment of drug products and drug substances 
are mandated by regulatory agencies across the 
globe. In fact, stability-testing issues are 
responsible for a number of audit findings by 
regulatory agencies. Stability testing problems 
are regularly cited in warning letters and 
sometimes results in costly product recall. 
Stability testing provides evidence that the 
quality of drug substance or drug product 
changes with time under the influence of various 
environmental conditions such as temperature, 
relative humidity etc. The stability study consists 
of a series of tests in order to obtain an assurance 
of stability of a drug product, namely 
maintenance of the drug product packed in it 
specified packaging material and stored in the 
established storage condition within the 
determined time period. (1,2)  
 
2.  Types  of stability study 
2.1 Physical stability: Physical instabilities 
possibilities are like, 
2.1.1 Crystal formation in pharmaceutical 
preparations: Causes of crystal formation in 
pharmaceutical formulations are like 
Polymorphism phenomena which are seen in 
Chloramphenicol, while in Saturated solution by 
different temperature precipitation of solute may 
occur and In suspension when very fine powder 
is used a part of suspending agent which dissolve 
and precipitated as crystals. 
2.1.2 Loss of volatile substances: Loss of 
volatile substance from pharmaceutical dosage 
forms like Aromatic waters, Elixirs, Spirits and 
some types of tablets which contain aromatic 
water cases physical instabilities.  
2.1.3 Loss of water: This can be seen in the 
dosage forms like, in saturated solution, by loss 
of water they become supersaturated and 
precipitate as crystals is formed. In emulsions, 
loss of water leads to separation of the two 
phases and change to other type while, in creams 
especially oil/water, they become dry by loss of 
water.  
2.1.4 Absorption of water :  In the different 
type of dosage form the absorption of water 
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cause physical instability by different 
mechanism. In Powders type of dosage form 
Liquefaction and degradation may occur as a 
result of absorption of water while in case of 
Suppositories which base made from hydrophilic 
substances as Glycerin, Gelatin, poly ethylene 
glycol, the consistency of these forms becomes 
jelly-like appearance and causes physical 
instabilities in pharmaceutical preparations.   
2.1.5 Change in crystalline form: Change in 
crystalline forms changes physical properties 
like solubility, melting point, bioavailability so 
change in crystalline form case physical 
instability. Example: Cocoa butter which is 
capable of existing in four polymorphic forms. 
Cocoa butter can crystallize in to six 
polymorphic forms designated as i-vi according 
to their stability and different physical 
characteristics. The chemical composition is 
identical in all forms; only the arrangement of 
the lipid molecules varies. The diverse 
polymorphs are formed under different 
crystallization condition.(3) 
2.2 Chemical stability: It involves various 
reactions like hydrolysis, reduction or 
fermentation which are influenced by moisture.(3) 
2.3 Microbial stability: Contamination 
from microorganisms is a big problem for all 
formulations containing moisture but it can be a 
bother in solid dosage forms also if some natural 
polymers are used because many natural 
polymers are fertile sources of microorganisms. 
In the type of hygienic manufacture carried out 
today where “Quality Assurance” is a 
prerequisite as per the GMP procedures, there 
are definite procedures to prevent microbial 
contamination in all formulations.(3) 
 
3.  Factors affecting drug stability 
3.1 Oxygen: Oxidation is the most important 
part of the drug degradation. Oxygen is present 
everywhere in the atmosphere and exposure to 
oxygen will decompose the drug substance that 
is not in their most oxidized state through auto-
oxidation. Oxygen is a diradical and most auto 
oxidation is a free radical reactions. 
Oxidation/reduction reaction involves transfer of 
electron, oxygen or hydrogen in substances. The 
process involves a radical chain reaction between 
molecular oxygen and the pharmaceutical drug 
candidate, a process known as auto-oxidation. 
The free radical process of auto-oxidation 
consists of a chain sequence involving three 
distinct types of reactions: initiation, 
propagation, and termination. The initiator 
produce a free radical to begin the chain initiator 
is used to accelerating auto-oxidation. For 
example, diazine. Oxidation of diazine occure by 
N-oxidation.(4) 
3.2 Water: The word hydrolysis literally 
means “splitting by water”. Drug substance 
having ester & amide functional groups within 
their structure undergoes hydrolysis reactions. 
For example solution of sodium acetate produces 
acetic acid and hydroxide ions. The reaction 
involving lactum group are fastest and are those 
followed by ester, amides and imides in that 
order and follows first order. These reactions are 
catalyzed by divalent metal ions, heat, light and 
high drug concentrations.(4) 
3.3 Temperature: Temperature has a high 
degree of influence on all variety of chemical 
reactions and usually they are accelerated by 
raise in temperature. To evaluate stability 
utilizing elevated temperatures and stress 
conditions are selected based on the Arrhenius 
expression a quantitative relationship of reaction 
rate and temperature. Based on this estimate, a 
10◦C increase in temperature results in a 
doubling of the reaction rate and a decrease in 
the reaction time by a factor of 2.(4) 
3.4 pH: PH influences the rate of 
decomposition of most drugs. Most of the drugs 
are stable between pH 4 and 8. Weekly acidic 
and basic drugs show good solubility when they 
are ionized and they also decompose faster when 
they are ionized.  So if the pH of a drug solution 
has to be adjusted to improve solubility and the 
resultant pH leads to instability then a way out of 
this tricky problem is to introduce a water 
miscible solvent into the product. It will increase 
stability by suppressing ionization, reducing the 
extreme pH required to achieve solubility, 
enhancing solubility and reducing the water 
activity by reducing the polarity of the solvent. 
For example, 20% propylene glycol is placed in 
chlordiazepoxide injection for this purpose. 
Reactions catalyzed by pH are monitored by 
measuring degradation rates against pH, 
temperature, ionic strength and solvent 
concentration constant. Some buffers such as 
acetate, citrate, lactate, phosphate and ascorbate 
buffers are utilized to prevent drastic change in 
pH.  Sometimes pH can have a very serious 
effect on decomposition. As little as 1 pH unit 
change in pH can cause a change of ten fold in 
rate constant. So when we are formulating a drug 
into a solution we should carefully prepare a pH 
– decomposition profile and then formulate the 
solution at a pH which is acceptable 
physiologically and stability-wise also.(4) 
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3.5 Moisture:  Water catalyses chemical 
reactions as oxidation, hydrolysis and reduction 
reaction, it also promotes microbial growth.(4) 
3.6 Light: Affects drug stability through its 
energy or thermal effect which lead to 
oxidation.(4) 
3.7 Concentration: Rate of drug degradation is 
constant for the solutions of the same drug with 
different concentration. So, ratio of degraded 
part to total amount of drug in diluted solution is 
bigger than of concentrated solution.(4) 
 
4.  Parameters for stability testing 
Different parameters like appearance, - assay and 
– degradation products should be evaluated for 
all dosage forms. Each dosage form is presented 
as a guide for the types of tests to be included in 
a stability study. In general, as well as 
preservative and antioxidant content if 
applicable. The microbial quality of multiple-
dose sterile and non-sterile dosage forms should 
be controlled. Challenge tests should be carried 
out at least at the beginning and at the end of the 
shelf-life. The list of tests presented for each 
dosage form is not intended to be exhaustive, nor 
is it expected that every listed test be included in 
the design of a stability protocol for a particular 
pharmaceutical product (for example, a test for 
odor should be performed only when necessary 
and with consideration for the analyst's safety).(5) 
 
5.  Regulatory requirement for stability 
study 
There are many regulatory guidelines for 
stability study mainly International Conference 
on Harmonization (ICH), World Health 
Organization (WHO), Association of South East 
Asian Nations (ASEAN) and European Agency 
for Evaluation of Medicinal and Health Products 
(EMEA). 
5.1 Objectives of the guidelines: These 
guidelines seek to exemplify the core stability 
data package required for registration of active 
pharmaceutical ingredients (APIs) and finished 
pharmaceutical products (FPPs), replacing the 
previous WHO guidelines in this area. However, 
alternative approaches can be used when they are 
scientifically justified. Further guidance can be 
found in International Conference on 
Harmonization (ICH) guidelines and in the 
WHO guidelines on the active pharmaceutical 
ingredient master file Procedure.  It is 
recommended that these guidelines should also 
be applied to products that are already being 
marketed, with allowance for an appropriate 
transition period, e.g. upon re-registration or 
upon re-evaluation. (6) 
5.2 Scope of these guidelines: These guidelines 
apply to new and existing APIs and address 
information to be submitted in original and 
subsequent applications for marketing 
authorization of their related FPP for human use. 
These guidelines are not applicable to stability 
testing for biological. (6) 
5.3 General principles: The purpose of stability 
testing is to provide evidence of how the quality 
of an API or FPP varies with time under the 
influence of a variety of environmental factors 
such as temperature, humidity and light. The 
stability programmed also includes the study of 
product-related factors that influence its quality, 
for example, interaction of API with excipients, 
container closure systems and packaging 
materials. In fixed-dose combination FPPs 
(FDCs) the interaction between two or more 
APIs also has to be considered. As a result of 
stability testing a re-test period for the API (in 
exceptional cases, e.g. for unstable APIs, a shelf-
life is given) or a shelf-life for the FPP can be 
established and storage conditions can be 
recommended. Various analyses have been done 
to identify suitable testing conditions for WHO 
Member States based on climatic data on the 
basis of which each Member State can make its 
decision on long-term (real-time) stability testing 
conditions.(6) 
5.4 Stability protocol/report: Protocol include 
following elements 
1. Information on batches tested (commercial 
formula) 
2. Unit composition (or cross-reference) 
3. Container-closure system (commercial) 
4. Literature and/or supporting data 
5. Stability specifications (only for Finished 
Pharmaceutical Products) 
6. Analytical methods – stability indicating 
(cross-reference) 
7. Stability plan (schedule) 
8. Tabulated test results (including 
specifications) 
9. Analysis/discussion of data (statistical if 
negative trend) 
10. Re-test or shelf-life proposal (including 
storage condition) 
11. Post approval commitments.(5) 
 
6.  Different regulatory guidelines for 
stability study 
6.1 ICH guideline: ICH guidelines define the 
stability data package for a new drug substance 
or drug product that is sufficient for a 
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registration application within the three regions 
of the EC, Japan and the United States. ICH 
guideline given for drug substance and drug 
product.(7-10) 
6.1.1 Stability testing requirements as per 
ICH guidelines 
(a) Drug substances 
Selection of batches: Data should be provided 
on at least three primary pilot scale batches. 
Storage conditions: Storage condition in 
different cases are given in table-1 
 
Table: 1 storage conditions in different case of 
stability study 
Different case of 
stability study 
Storage conditions 
General case 
      Long term: 25°C ± 2°C/60%RH ± 5% RH 
or 30°C±2°C/65%RH±5% RH 
Intermediate: 30°C ± 2°C/65% RH ±5% RH 
Accelerated: 40°C ± 2°C/75%RH ±5% RH 
For drug substance intended to be stored in Refrigerator 
      Long term 5°C ± 3°C 
Accelerated 25°C ±2°C/60%RH ± 5% RH 
For drug substance intended to be stored in freezer 
Long term - 20°C ± 5°C 
 
Stress testing 
Stress testing recommendations: 
Temperature: Temperature above accelerated 
temperature (50˚C, 60˚C, 70˚C, etc.) 
Humidity: 25˚C/75% RH and 25˚C/90% RH 
Oxidation: Wide range of pH 
Photo stability testing should be carried out on a 
single batch. 
Testing frequency 
 Long term studies: 0, 3, 6, 9, 12, 18, 24 
months and annually through the proposed 
re-test          period. 
Accelerated: 0, 3, 6 months 
Intermediate: 0, 6, 9, 12 months 
Container closure system: Stability testing 
should be carried out in the same container 
closure system as that proposed for storage and 
distribution. 
Stability commitment: If the data does not cover 
the proposed retest period granted at the time of 
approval, a commitment should be made to 
continue the stability studies post approval. 
Statements/ labeling: A storage statement 
should be established based on the stability 
evaluation of the drug substance. 
(b) Drug products or finished pharmaceutical 
products: 
Selection of batches: Data should be provided 
on at least three primary batches. Two should be 
at least pilot scale batches. 
Storage condition: Storage conditions for 
general case, for the product intended to be 
stored in refrigerator and freezer is same as that 
for drug substance. 
Drug products packaged in semi-permeable 
containers: 
Accelerated: 40°C±2°C/NMT 25%RH 
 
Stress testing 
Temperature: 50˚C or 60˚C for 1 month 
Temperature/humidity: 40˚C/75%RH, 
25˚C/80%RH 
Photo stability testing should be carried out. 
Testing frequency: Same as that of drug 
substances. 
Container closure system: Container closure 
system for testing should be same as that 
proposed for marketing including any secondary 
packaging. 
Stability commitment: If the data does not cover 
the proposed shelf life granted at the time of 
approval, a commitment should be made to 
continue the long term studies through the 
proposed shelf life and the accelerated studies 
for 6 months post approval. 
Statements/ labeling: Same as drug 
substances.(7-10) 
 
6.2 WHO guideline: WHO guidelines apply to 
new and existing API’s and their related FPP’s 
for human use. WHO guideline is derived from 
ICH parent guideline, they have some significant 
differences which define its individuality as a 
separate guideline. The differences were 
observed in the parameters like selection of 
batches, storage conditions and statements and 
labeling. (5,11) 
6.3 ASEAN guidelines: Association of South 
East Asian Nations (ASEAN) guideline mainly 
focuses on the requirements for stability testing 
of drug products along with new chemical 
entities (NCE’s). The differences were observed 
in stress testing, selection of batches and real 
time storage conditions. This guideline addresses 
the information to be submitted an application 
for marketing authorization of drug products in 
ASEAN countries including examples of a 
protocol of stability study, a report format, 
reduced design and extrapolation of data, and 
examples of types, thickness and permeability 
coefficient which are covered in Annexes. The 
drug products covered in this guideline include 
NCE, Generics and Variation. But exclude drug 
products containing vitamin and mineral 
preparations. (12) 
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6.4 EMEA guidelines: This guideline is an 
extension of the note for guidance on stability 
testing of new veterinary drug substances and 
medicinal products 
(EMEA/CVMP/VICH/899/99-Rev.1) and sets 
out the stability testing requirements for existing 
active substances and related finished products. 
For the purposes of this guideline, an existing 
active substance is one that has been authorized 
previously through a veterinary medicinal 
product within the European Community. This 
guideline is applicable to chemical active 
substances and related finished products, herbal 
drugs, herbal drug preparations and related 
herbal medicinal products and not to 
radiopharmaceuticals, biological and products 
derived by biotechnology. The guideline seeks to 
exemplify the core stability data package 
required for such active substances and finished 
products, but leaves sufficient flexibility to 
encompass the variety of different practical 
situations that may be encountered due to 
specific scientific considerations and 
characteristics of the materials being evaluated. 
Alternative approaches can be used when there 
are scientifically justifiable reasons. The 
guideline addresses the information to be 
submitted in registration applications for existing 
active substances and related finished products. 
Most of the parameters for drug substance and 
drug products are followed same as the ICH 
guideline like stress testing, testing frequency, 
stability commitment, statement/labeling. Only 
difference in the parameters like selection of 
batches and storage conditions. (13)  
6.5 Comparison of all guidelines (7-13): Stability 
testing (ST) requirements are presented by 
International Conference on Harmonization 
(ICH) and different regulatory agencies like, 
World Health Organization (WHO), Association 
of South East Asian Nations (ASEAN) and 
European Agency for Evaluation of Medicinal 
and Health Products (EMEA). Most of the 
stability requirements for WHO, ASEAN, and 
EMEA are similar to the ICH guideline, except 
for the parameters like selection of batches and 
storage conditions. These differences given in 
table-2 
 
Conclusion  
From the above work it can be concluded that 
stability study regulatory requirements are 
important for defined the capacity of a drug 
substance or drug product to remain within the 
established specifications to maintain its identity, 
strength, quality and purity throughout the retest 
or expiration dating period. Various factors 
affect the stability of drugs are water, oxygen, 
temperature, pH, moisture and concentration. 
Review compares the stability testing (ST) 
requirements of International Conference on 
Harmonization (ICH) with other international 
regulatory agencies like World Health 
Organization (WHO), Association of South East 
Asian Nations (ASEAN) and European Agency 
for Evaluation of Medicinal and Health Products 
(EMEA). ICH guideline is parent guideline and 
from which WHO guideline is derived. ICH 
guideline defines stability testing requirements 
for new drug substances and drug products 
whereas WHO guideline applies to both new and 
existing API’s and their related finished products 
and ASEAN guideline mainly focuses on the 
stability testing requirements for drug products 
which include generics and variations along with 
NCEs. The differences were observed in the 
following parameters: selection of batches, 
storage conditions and statements and labeling. 
 
Table:2 Comparison of stability study parameters with respect to different regulatory agencies 
Parameters ICH WHO ASEAN EMEA 
Selection of
batches 
Data from atleast
three primary  
batches of the
new Drug
substance 
should be  
provided. 
Data from at least two 
primary batches should be 
Provided for stability 
testing of existing API’s. 
Data on at least two pilot 
scale batches are 
acceptable 
for conventional dosage 
forms and for product 
Containing stable drug 
substances. 
Option a: Drug substance 
(Official): Stability 
information from  at least two 
production scale batches. 
Drug product: For 
conventional dosage form and 
when drug substances are 
known to be stable, stability 
data on at least two pilot scale 
batches are acceptable. 
Option b: Drug substance 
(not official): at least three 
pilot scale batches use. 
Drug product: For critical 
dosage forms or when active 
substances are known to be 
unstable, three primary 
batches are taken. 
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Storage 
conditions 
Long term:
25°C± 
2°C/60% RH ±
5% RH or 
30°C± 
2°C/65% RH ±
5% RH 
Long term 
25°C±2°C/60% RH ± 5% 
RH or 30°C± 2°C/65% 
RH ± 5% RH or 
30°C±2°C/75% RH ± 5% 
RH 
Product stored in 
permeable container: 
30°C±2°C/75%RH ± 5% 
RH 
Drug substance: 
Long term storage conditions: 
minimum time covered by 
data at the time of submission 
should be 6 months for both 
option a and b. 
Accelerated 
25°C± 
2°C/60% RH ±
5% RH 
Accelerated storage: 
25°C ± 2°C/60% RH ± 
5% RH or 
30°C±2°C/65% RH ± 5% 
RH or  
30°C± 2°C/75% RH ± 5% 
RH 
For NCE (real time 
storage), generics and 
variations: 
30°C ± 2°C/75%RH ± 5% 
RH 
Drug product: 
Long term storage conditions: 
minimum time covered by 
data at the time of submission 
should be - Option a: 6 
months, Option b:12 months 
Stress testing Temperature: 
above 
accelerated 
storage 
conditions 
(50ºC, 60ºC,
70ºC) 
Humidity: 
25˚C/75%RH 
and 
25˚C/90%RH 
Same as ICH Stress testing conditions is 
40°C± 2°C/75% 
RH±5%RH which is same 
as accelerated storage 
Conditions. 
Same as ICH 
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